Pharmacological inhibition of fatty acid oxidation reduces atherosclerosis progression by suppression of macrophage NLRP3 inflammasome activation
Philipp J. Hohensinner(Ludwig Boltzmann Institute for Age Research), Walter S. Speidl(University of Applied Sciences St Pölten), Stefan Stojković, Johann Wojta(Medical University of Vienna), Laura Goederle(Medical University of Vienna), Max Lenz(Ludwig Boltzmann Institute for Digital Health and Prevention), Patrick Haider(Medical University of Vienna), Manuela Richter(Medical University of Vienna), Daniel Peter Ramsmayer(Medical University of Vienna), Bruno K. Podesser(Ludwig Boltzmann Institute for Cardiovascular Research), Christoph J. Binder(Medical University of Vienna), Julia Mayer(Medical University of Vienna), Kurt Huber(Sigmund Freud Privatuniversität Wien), Michael B. Fischer(Universität für Weiterbildung Krems), Smriti Sharma(Medical University of Vienna), Christoph Kaun(University of Vienna), Christian Hengstenberg(Medical University of Vienna), Mira Brekalo(Medical University of Vienna), Manuel Salzmann(Medical University of Vienna)
Cited by 25
Related Papers
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2020|1.5k
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
|Circulation|2011|1.1k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|755